Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Share-based Compensation (IS) (2022 - 2024)

Historic Share-based Compensation (IS) for Indivior Pharmaceuticals (INDV) over the last 3 years, with Q4 2024 value amounting to $6.0 million.

  • Indivior Pharmaceuticals' Share-based Compensation (IS) changed 0.0% to $6.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $24.0 million, marking a year-over-year increase of 909.09%. This contributed to the annual value of $24.0 million for FY2024, which is 909.09% up from last year.
  • Indivior Pharmaceuticals' Share-based Compensation (IS) amounted to $6.0 million in Q4 2024, which was down 0.0% from $7.0 million recorded in Q3 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Share-based Compensation (IS) peaked at $7.0 million during Q3 2024, and registered a low of $4.0 million during Q4 2022.
  • Moreover, its 3-year median value for Share-based Compensation (IS) was $5.5 million (2022), whereas its average is $5.5 million.
  • Within the past 5 years, the most significant YoY rise in Indivior Pharmaceuticals' Share-based Compensation (IS) was 5000.0% (2023), while the steepest drop was 0.0% (2023).
  • Quarter analysis of 3 years shows Indivior Pharmaceuticals' Share-based Compensation (IS) stood at $4.0 million in 2022, then skyrocketed by 50.0% to $6.0 million in 2023, then changed by 0.0% to $6.0 million in 2024.
  • Its Share-based Compensation (IS) stands at $6.0 million for Q4 2024, versus $7.0 million for Q3 2024 and $6.0 million for Q2 2024.